Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
Best Penny Stocks To Buy? 4 To Watch With Targets Up To 397%
04:21pm, Thursday, 16'th Feb 2023 PennyStocks
Penny stocks to buy according to 4 analysts in the stock market in February 2023.
The post Best Penny Stocks To Buy? 4 To Watch With Targets Up To 397% appeared first on Penny Stocks to Buy, Picks, Ne
Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth
03:01pm, Thursday, 16'th Feb 2023 Zacks Investment Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best Penny Stocks To Buy? 4 To Watch With Targets Up To 397%
11:21am, Thursday, 16'th Feb 2023
Penny stocks to buy according to 4 analysts in the stock market in February 2023. The post Best Penny Stocks To Buy?
G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
03:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dow Gains Over 300 Points; S&P 500 Up 1%
07:22pm, Monday, 13'th Feb 2023 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday.
The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500 al
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
07:12pm, Monday, 13'th Feb 2023 Benzinga
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
Top Ships Inc. (NASDAQ: TOPS) gained 37.2% to $1.7985 after the company entered int
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
05:24pm, Monday, 13'th Feb 2023 Benzinga
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday.
The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500 al
US Stocks Open Higher; Dow Jumps 200 Points
03:23pm, Monday, 13'th Feb 2023 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.59% to 34,069.23 while the NASDAQ rose 0.65% to
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
11:00am, Monday, 13'th Feb 2023 GlobeNewswire Inc.
- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through
Pharma Stock Hits Record Low Due to Pulled Study
10:22am, Monday, 13'th Feb 2023
The shares of G1 Therapeutics Inc (NASDAQ:GTHX) were last seen down 53.6% at $3.33, after the company announced plans to discontinue a drug study for the treatment of a type of colon cancer , with pl
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:46pm, Wednesday, 01'st Feb 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
03:00pm, Monday, 30'th Jan 2023 Benzinga
Upgrades
According to B of A Securities, the prior rating for Flowserve Corp (NYSE:FLS) was changed from Neutral to Buy. Flowserve earned $0.09 in the third quarter, compared to $0.29 in the year-ago
G1 Therapeutics: Poised For A Turnaround
05:22am, Saturday, 21'st Jan 2023 Seeking Alpha
G1 Therapeutics' shares have experienced much volatility in the past year. While it has tremendous risk as a speculative play, read why I rate GTHX stock a Buy.
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
12:00pm, Wednesday, 11'th Jan 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
11:30am, Monday, 09'th Jan 2023 GlobeNewswire Inc.
- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion -
